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CD56 expression in breast cancer 
induces sensitivity to natural 
killer-mediated cytotoxicity 
by enhancing the formation of 
cytotoxic immunological synapse
Ghina Taouk1, Ola Hussein2, Moussa Zekak3, Ali Abouelghar1, Yasser Al-Sarraj4, 
Essam M. Abdelalim4,5 & Manale Karam1,4
We examined the potential value of the natural killer (NK) cell line; NK-92, as immunotherapy tool 
for breast cancer (BC) treatment and searched for biomarker(s) of sensitivity to NK-92-mediated 
cytotoxicity. The cytotoxic activity of NK-92 cells towards one breast precancerous and nine BC cell 
lines was analyzed using calcein-AM and degranulation assays. The molecules associated with NK-92-
responsiveness were determined by differential gene expression analysis using RNA-sequencing and 
validated by RT-PCR, immunostaining and flow cytometry. NK-target interactions and immunological 
synapse formation were assessed by fluorescence microscopy. Potential biomarker expression was 
determined by IHC in 99 patient-derived BC tissues and 10 normal mammary epithelial tissues. Most 
(8/9) BC cell lines were resistant while only one BC and the precancerous cell lines were effectively 
killed by NK-92 lymphocytes. NK-92-sensitive target cells specifically expressed CD56, which ectopic 
expression in CD56-negative BC cells induced their sensitivity to NK-92-mediated killing, suggesting 
that CD56 is not only a biomarker of responsiveness but actively regulates NK function. CD56 adhesion 
molecules which are also expressed on NK cells accumulate at the immunological synapse enhancing 
NK-target interactions, cytotoxic granzyme B transfer from NK-92 to CD56-expressing target cells and 
induction of caspase 3 activation in targets. Interestingly, CD56 expression was found to be reduced in 
breast tumor tissues (36%) with strong inter- and intratumoral heterogeneity in comparison to normal 
breast tissues (80%). CD56 is a potential predictive biomarker for BC responsiveness to NK-92-cell based 
immunotherapy and loss of CD56 expression might be a mechanism of escape from NK-immunity.
In the past decades, the advances in molecular biomarkers and the progress in treatment modalities have together 
contributed to improvements in breast cancer diagnosis, classification, and individualized therapy, and as a con-
sequence in patient overall survival1–3. However, despite the marked decline in the breast cancer death rates over 
time, this disease remains the second leading cause of cancer death among women4. In fact, in many cases tumors 
do not respond to the currently available treatments or relapse after initial response5. Therefore, new treatment 
strategies are still required to eliminate these resistant tumors and improve clinical outcomes in patients. More 
recently, some experimental and clinical studies suggest a potential value of natural killer (NK)-cell based immu-
notherapy to eliminate residual breast tumor cells3.
NK cells are lymphocytes of the innate immune system specialized in the detection and clearance of 
“modified-self ” cells, such as cancer and virus-infected cells, without any prior-sensitization6. NK cells develop 
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mainly in the bone marrow and mature NK cells are exported to the periphery and are found in the blood, all of 
the lymphoid organs and some parenchymal tissues (lungs and liver)7. NK cells directly recognize their target 
through a complex array of regulatory (activating and inhibitory) receptors that monitor cell surfaces of autolo-
gous cells for an aberrant expression of self-ligands and cell stress markers, which frequently occurs in tumors8–10. 
Following NK-target recognition, NK cells adhere to their target to create an immunological synapse where the 
regulatory receptors spatially cluster in order to increase the efficacy of intracellular signaling11,12. NK activation 
results in the polarization of cytotoxic granules (containing cytolytic effector molecules such as granzymes and 
perforins) toward the immunological synapse and in their directed exocytosis. Thus, following membrane per-
turbation by perforin at the immune synapse, granzymes enter the target cells where they can cleave numerous 
substrates in the cytoplasm and nucleus leading to the induction of apoptosis13. Although the perforin/granzyme 
pathway is the main mechanism of NK-mediated cytotoxicity, NK cells can also induce apoptosis in target cells 
through the tumor necrosis factor (TNF) receptor pathway14. Furthermore, active NK cells can secrete a variety of 
cytokines and chemokines that might exert direct anti-tumor activity or promote innate and adaptive responses15.
Following the progress in understanding the biology and anti-tumoral function of NK cells, these lympho-
cytes have recently become a powerful cell-based cancer immunotherapy tool16. However, so far, the success of 
NK cell-based immunotherapy has largely been confined to hematological cancers17,18, and to a lesser extent to 
neuroblastoma19 and glioblastoma20,21. On the other hand, other types of cancer such as breast cancer were found 
to be resistant to NK cell-based therapy3,16,22–24.
In addition to the cancer type-dependent therapeutic potential of NK cells, other major overall challenges 
in NK cell-based therapy include the difficulty to obtain sufficient numbers of clinical-grade and functionally 
active primary NK cells for infusion in addition to the inter- and intra-donor variabilities25,26. Alternatively, a 
well-characterized cell line; NK-92, established from patient with clonal NK-cell lymphoma can be easily and repro-
ducibly expanded from a good manufacturing practice (GMP)-compliant cryopreserved master cell bank26–28. 
NK-92 cell line is highly cytotoxic; it expresses high levels of cytolytic pathway molecules, such as perforin and 
granzyme B29,30, lacks almost all killer cell immunoglobulin-like receptors (KIRs) and expresses major activating 
receptors (such as NKG2D, NKp30, NKp46)29. NK-92 cytotoxic potency was demonstrated against a wide range of 
tumor types including leukemia, lymphoma, myeloma, melanoma and prostate cancer in vitro30,31. Furthermore, 
in large number of preclinical studies using SCID mice, infusion of the parental NK-92 cells has been shown to 
eliminate AML31, myeloma32 and melanoma33. Moreover, subsequent phase I clinical testing demonstrated safety 
of NK-92 infusions even at high doses and clinically significant responses were seen in a subset of patients with 
melanoma, lung cancer, kidney cancer and AML26,34,35. For these reasons, NK-92 represents an ideal tool for can-
cer immunotherapy; however, its cytotoxic potential towards breast cancer cells is still unknown.
The aim of this study was to analyze the cytotoxic activity of NK-92 cells towards breast cancer cells and 
to identify potential mechanism(s) and predictive biomarker(s) of breast cancer-sensitivity to NK-92-mediated 
cytotoxicity. We focused on the role of the adhesion molecule and archetypal phenotypic marker of NK cells; i.e. 
the cluster differentiation 56 (CD56), also known as neural cell adhesion molecule-1 (NCAM-1), which role in 
NK cell cytotoxic function was still unknown.
Results
Different susceptibilities of breast cancer cell lines and overgrowing precancerous mammary 
epithelial cells to NK-92-mediated cytotoxicity. To check the potential value of the NK-92 cell line as 
immunotherapy tool for breast cancer treatment, the cytotoxic activity of NK-92 cells was tested towards nine 
human breast cancer cell lines (MCF-7, T47D, HCC1500, BT474, SKBR3, HCC1954, MDA-MB-231, BT20 and 
BT549). A cell line of human mammary epithelial cells immortalized with the human telomerase reverse tran-
scriptase; hTERT (hTERT-HME1) was also used as target to test the cytotoxic activity of NK-92 cells towards 
overgrowing but precancerous mammary epithelial cells. In fact, the acquisition of constitutive telomerase expres-
sion is a critical step during the malignant transformation of human cells. It contributes to cancer development 
by maintaining stable telomere length and unlimited cell proliferation but also by rendering the cells more sus-
ceptible to oncogenic transformation36. A normal primary human mammary epithelial cell line (PMEC) was 
used as negative control and the K562 leukemic cell line was used as positive control as it is known to be a highly 
sensitive target for NK cells37. As shown in Fig. 1, NK-92 cells very effectively killed K562 and hTERT-HME1 cells 
(50% cytotoxicity reached at very low NK-92:Target ratios ≤ 0.3:1 and 2.2:1, respectively). However, the normal 
mammary epithelial cells and most breast cancer cell lines (except for BT549 and MCF-7) were relatively resist-
ant to NK-92 cytotoxicity as 50% cytotoxicity was not reached even at high NK-92:Target ratio (20:1). Although 
BT549 and MCF-7 breast cancer cells were responsive to NK-92 cytotoxicity, they were by far less sensitive than 
the hTERT-immortalized mammary epithelial cells (50% cytotoxicity reached at NK-92:Target ratios of ~8:1 and 
17:1, respectively vs 2.2:1).
The high sensitivity of hTERT-immortalized mammary epithelial cells and BT549 breast 
cancer cells to NK-92-mediated cytotoxicity is associated with enhanced NK-92 degran-
ulation. To gain insight into the mechanism of increased sensitivity of hTERT-HME1 and BT549 cells to 
NK-92-mediated lysis, we first checked whether these target cells could better induce NK activation in com-
parison to the NK-92-resistant breast cancer cells, rather than being only more sensitive to apoptotic death. 
Therefore, following coculture with the different target cells, CD107a expression on the surface of NK-92 cells 
(a hallmark of NK activation and degranulation)38 was assessed by flow cytometry (Fig. 2). Results showed 
approximately 12-, 11- and 7-fold increase in CD107a expression on the surface of NK-92 cells after 2 h coculture 
with K562, hTERT-HME1 and BT549 target cells, respectively in comparison to NK-92 cultured without target 
cells (Fig. 2A,B). When cocultured with the NK-92-resistant (MDA-MB-231, SKBR3, HCC1954, T47D, BT20, 
BT474 and HCC1500) or the less sensitive (MCF-7) breast cancer cells, target-induced NK-92 degranulation 
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was very low (≤3.5-fold increase in CD107a surface expression) (Fig. 2A,B). These findings suggest that the 
NK-92-sensitive hTERT-immortalized epithelial cells (hTERT-HME1) and cancer cells (BT549) of mammary 
origin as for the K562 leukemic cells are more potent in inducing NK-92 cell degranulation compared to the 
relatively more resistant breast cancer cells, which can be the consequence of an increased NK recognition and 
activation by these target cells.
Figure 1. Cytotoxic activity of NK-92 cells towards breast cancer cells and mammary epithelial cells. NK-92 
cells were cocultured with calcein-AM-prelabeled target cells at different NK-92:target ratios and the specific 
target cell lysis was determined after 4 h. (A) Results presented are mean percentages of cytotoxicity ± SD for 
three to nine independent experiments performed each in triplicates. (B) Bar graph showing the minimal 
significant NK-92:target ratios to cause lysis of 50% target cells.
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Specific association of CD56 expression in breast precancerous and cancerous cells with high 
sensitivity to NK-92-mediated killing. Target cells are recognized by NK cells and can induce the 
activity of these effectors through regulatory receptors/ligands and adhesion molecules expressed on their sur-
face8,39. Thus, such molecules might be involved in conferring the high sensitivity of hTERT-HME1 and BT549 to 
NK-92-mediated cytotoxicity.
Figure 2. Degranulation state of NK-92 cells after coculture with breast cancerous and precancerous cells. 
NK-92 cells were cocultured with CFSE-labeled NK-92-sensitive (red) and NK-92-resistant (blue) target cells at 
1:1 ratio for 2 h. Next, CD107a expression on the surface of NK-92 cells was assessed by flow cytometry.  
(A) Representative experiments of at least three independent experiments showing the percentage of CD107a-
positive NK-92 cells. (B) Graph presenting the fold-increase in target-induced CD107a-positive NK-92 cells 
(relative to spontaneous CD107a expression) ± SD for at least three independent experiments. *p < 0.05; 
**p < 0.01; ***p < 0.001 versus BT549 cells.
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In a first attempt to analyze NK-92 degranulation (CD107a surface expression) following coculture with 
breast cancer target cells, we used, in association with CD107a staining, CD56 (the archetypal phenotypic marker 
of NK cells) staining to discriminate between NK-92 (CD56-positive) and breast cancer cells (expected to be 
CD56-negative) (Supplementary Fig. 1A). The results showed that when NK-92 cells were cultured without 
target cells, all the cells (>99.8%) were CD56-positive, as expected. When NK-92 cells were cocultured with 
NK-92-resistant cells at NK-92:target ratio of 1:1, about half of the population was CD56-positive (correspond-
ing to NK-92 cells) and the other half was CD56-negative (corresponding to breast cancer cells). However, 
unexpectedly, when NK-92 cells were cocultured with NK-92-sensitive cells, almost all the cells (>95%) were 
CD56-positive, suggesting that the NK-92-sensitive breast cancer cells would express the adhesion mole-
cule CD56. Consistently, differential gene expression analysis by RNA-sequencing revealed that CD56 mRNA 
is indeed highly and specifically expressed in NK-92-sensitive cells (hTERT-HME1 and BT549) but absent 
(SKBR3, BT20, MCF-7, MDA-MB-231, BT474, T47D and HCC1500) or very faintly expressed (HCC1954) in 
the NK-92-resistant breast cancer cells (Supplementary Fig. 1B). The specific expression of CD56 mRNA in these 
NK-92-sensitive cells was validated by RT-PCR (Fig. 3A) and confirmed at the protein level by immunofluores-
cence (Fig. 3B).
Next, as the expression of CD56 at the surface of target cells is critical for its role in cell adhesion, we checked 
its presence at the surface of NK-92-sensitive target cells by flow cytometry which was performed on viable, 
non-permeabilized cells and by using two different antibodies that bind to different epitopes in the extra-
cellular domain of CD56 (Fig. 3C). Results showed that CD56 is expressed at the surface of approximately 
95.45% and 88.8% of the NK-92-sensitive hTERT-HME1 and BT549 cells, respectively. In contrast, among the 
NK-92-resistant breast cancer cells, only a small portion of the HCC1954 cell line (approximately 14.5%) express 
CD56 on their surface while all other resistant cells (MCF-7, MDA-MB-231, SKBR3, T47D, BT20 and BT474) 
are negative for CD56 protein expression. Furthermore, as expected most NK-92 cells (approximately 95.6%) 
expressed CD56 on their surface. Interestingly, in contrast to the NK-92-sensitive hTERT-immortalized epi-
thelial and cancer cells of mammary origin, the leukemia cell line K562 didn’t express CD56 (Supplementary 
Fig. 1B, Fig. 3A,C). Furthermore, the human primary mammary epithelial cells (PMECs) also expressed CD56 
(Supplementary Fig. 1B and Fig. 3A). Taken together, these results show for the first time that CD56 adhesion 
molecule can be expressed in a subset of normal, precancerous and cancerous cells of mammary origin and 
suggest its strong association with sensitivity to NK-92-mediated killing, which seems to be tissue type-specific.
Increased expression of CD56 at the immunological synapse and association with cytotoxic 
granzyme B transfer from NK-92 into target cell and caspase 3 activation. Next, we checked 
whether CD56 expression in target cells is merely a marker of sensitivity to NK-92-mediated cytotoxicity or 
whether it is actively involved in the immune effector function. As CD56 is an adhesion molecule that can regu-
late cellular function through homophilic interactions40, we hypothesized that CD56 molecules on NK-92 cells 
and those on target cells would interact together to enhance the formation and stabilization of the immune syn-
apse between these effector and target cells. To test this hypothesis, CD56-negative (MCF-7, MDA-MB-231 and 
SKBR3) and CD56-expressing (hTERT-HME1) target cells were labeled with CFSE and cocultured with NK-92 
cells at 1:1 effector-to-target ratio for 2 hours before immunostaining for CD56 and fluorescent microscopy 
analysis. Results showed that the rate of immune synapse formation is significantly higher when NK cells are 
co-cultured with CD56-positive target cells (13.99%) than CD56-negative target cells (2.12%) (Fig. 4D). Thus, 
CD56 expression in target cells associates with enhanced immune synapse formation and/or stabilization.
Analysis of the localization of CD56 within the NK-target conjugates showed that this adhesion molecule 
strongly accumulates at the effector-target intercellular contacts specifically when target cells are CD56-positive 
but not when they are CD56-negative (Fig. 4A). Next, to further confirm that these interactions correspond to 
the immunological synapse the cocultures of NK-92 and target cells were co-stained for actin (to visualize actin 
cytoskeleton polymerization at immune synapse41; and CD56 then analyzed by fluorescent microscopy (Fig. 4B). 
Results showed that indeed CD56 molecules strongly accumulate at the immune synapse, which was accompa-
nied by granzyme B cytotoxic molecule transfer from NK-92 to the CD56-expressing target cells (Fig. 4C).
Following their delivery into the target cells at immune synapse, granzymes can induce apoptosis by different 
pathways13. A common factor between these granzyme-induced apoptosis pathways, pro-caspase 3 is the main 
caspase that will be cleaved and activated downstream of granzyme B, which is thought to be a critical first step 
in cytotoxic lymphocyte-induced apoptosis13. Therefore, to further confirm the association of CD56 expression 
in target cells with enhanced activation and cytotoxic function of NK-92 cells, active caspase 3 levels in target 
cells cocultured or not with NK-92 cells were measured by flow cytometry (Fig. 5). Our results showed that 
while active caspase 3 was absent in almost all of the target cells (98.34–99.36%) (Fig. 5A, upper plots), follow-
ing coculture with NK-92, it was strongly increased in CD56-positive target cells (19.8–21.4% active caspase 
3-positive cells) but not in CD56-negative target cells (2.42–4.98% active caspase 3-positive cells) (Fig. 5A). 
Overall, NK-92-induced caspase 3 activation was 3.13 to 7.5-fold higher in CD56-positive target cells in compari-
son to CD56-negative target cells (Fig. 5B). Taken together, these results indicate that CD56 strongly accumulates 
at the immunological synapse and associates with cytotoxic granzyme B transfer from NK-92 into CD56-positive 
target and with a higher rate of NK-92-induced apoptosis. Thus, target-expressed CD56 might be involved in the 
formation and stabilizing of the immunological synapse allowing enhanced NK activation and stimulation of 
target cell death.
Induction of CD56 expression in breast cancer cells enhances their sensitivity to NK-92-mediated 
cytotoxicity. In order to check the potential direct NK-sensitizing role of CD56 in breast cancer cells, this 
adhesion molecule was transiently overexpressed in CD56-negative MCF-7 and MDA-MB-231 cells. Then, the 
potential localization of CD56 at the immune synapse and its role in target responsiveness to NK-92-mediated 
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Figure 3. Specific expression of CD56 adhesion molecule on breast precancerous and cancerous cells 
exhibiting high sensitivity to NK-92-mediated killing. (A) Analysis of CD56 mRNA expression in NK-92, 
hTERT-immortalized epithelial mammary cells (hTERT-HME1) and breast cancer cells (BT549, SKBR3, BT20, 
HCC1954, MCF-7, MDA-MB-231, BT474, T47D and HCC1500) by RT-PCR. The expression of GAPDH 
gene was used as housekeeping control. The RT-PCR agarose gel electrophoresis images are those of a typical 
experiment and the results presented in the corresponding densitometry bar graph are the means ± SD for three 
independent experiments. (B) Representative immunofluorescence images of NK-sensitive (hTERT-HME1 and 
BT549) and NK-resistant (HCC1954, BT20 and SKBR3) target cells that were fixed, permeabilized and stained 
for CD56 and nuclei (DAPI). (C) Analysis of CD56 protein expression on the surface of viable NK-92 cells 
and the indicated target cells by flow cytometry using two different antibodies (Ab1 and Ab2) that recognize 
different epitopes on the extracellular portion of this protein. The histograms presented indicate the percentage 
of CD56-positive cells and are representative results from two independent experiments.
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cytotoxicity were analyzed by immunofluorescence microscopy and calcein-AM cytotoxicity assay, respectively 
(Fig. 6). We found that after two days of transfection with CD56 containing plasmid (pCMV3-CD56), around 
40.3%-46.4% of breast cancer cells expressed CD56 (Fig. 6A) that was strongly concentrated at the immune synapse 
between NK-92 and target cells (Fig. 6B). Furthermore, the rate of synapse formation (Fig. 6C) and the percent-
age of NK-92-mediated cytotoxicity (Fig. 6D) were strongly increased (by approximately 3.4-fold and 2.11-fold, 
respectively) for both CD56-transfected MCF-7 and MDA-MB231 cells in comparison to empty vector-transfected 
control cells. Thus, these results validate the role of CD56 in immune synapse formation and/or stabilization and in 
increasing the sensitivity of breast cancer cells to NK-92-mediated cytotoxicity.
Analysis of CD56 expression in patient-derived breast cancer tissues and association with clin-
icopathological features and patient survival. The data presented above suggests that breast tum-
ors expressing CD56 might be more sensitive to NK-mediated cytotoxicity and thereby these patients might 
be potential candidates for NK-92 cell-based immunotherapy. However, to our knowledge, CD56 expression in 
breast tissues was not previously reported. Therefore, to get some insight into the potential relevance of CD56 
as predictive biomarker for NK-sensitivity in breast cancer, we analyzed its expression status in breast cancer 
tissues using breast carcinoma microarray, containing 100 cases of invasive ductal carcinoma and 10 adjacent 
Figure 4. CD56 expression at immunological synapse and association with granzyme B transfer from 
NK-92 into CD56-positive target cells. CD56-expressing (hTERT-HME1) and/or CD56-negative (MCF-7, 
MDA-MB-231 and/or SKBR3) target cells were labeled (panels A and C) or not (panel B) with CFSE and 
cocultured with NK-92 cells at 1:1 effector-to-target ratio for 2 hours. Cells were then transferred to poly-L-
lysin-coated coverslips, fixed, permeabilized and stained as indicated for CD56 (panels A and B), actin (panel 
B), granzyme b (panel C) and nuclei (DAPI) (panels A, B and C) before analysis by fluorescent microscopy. 
Images is panel A are for MCF-7 and MDA-MB-231 (CD56-negative targets) and hTERT-HME1 (CD56-
positive target) and correspond to representative fields from two or three independent experiments. Images 
in panel C are for three different synapses observed after 2 hours in the same coculture of NK-92 and hTERT-
HME1. (D) Graph presenting the mean rates of synapse formation ± SD obtained from six representative fields 
for CD56-positive target (hTERT-HME1) and nine representative fields for CD56-negative targets (three fields 
for each cell line MCF-7, MDA-MB-231 and SKBR3). ***p < 0.001.
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normal breast tissues (Supplementary Fig. 2 and Table 1). The immunohistochemical analysis showed that 24.2% 
of tumor tissues expressed high levels of CD56, 12.1% expressed moderate levels of CD56, and 63.7% expressed 
very low levels or were completely negative for CD56 (Table 1). Noteworthy, 80% (8 out of 10) of the normal 
breast tissues expressed CD56 (Supplementary Fig. 2), consistently with the primary mammary epithelial cell line 
(PMEC) (Fig. 3A and Supplementary Fig. 1B). However, in contrast to breast tumor tissues that mostly expressed 
low levels of CD56, 60% of breast normal tissues were found to express high levels of CD56, 10% expressed mod-
erate levels of CD56 and 30% expressed very low levels of CD56 (Supplementary Fig. 2).
Next, the possible relationship between CD56 expression and clinicopathological variables that were available 
for the microarray was determined (Table 1). However, no relationship was found between the expression pattern 
of CD56 and all available classical pathological and clinical parameters (i.e. patient age, tumor size, lymph node 
status, tumor grade, ER status and PR status).
Figure 5. Association of CD56 expression in target cells with increased NK-92-induced caspase 3 activation. 
NK-92 cells were coculture or not with CFSE-labeled target cells for 2 hours at 1:1 effector-to-target ratio then 
NK-induced and spontaneous active caspase 3 levels in target cells were measured by flow cytometry. (A) 
Representative histograms showing the percentage of active caspase 3-positive (aCasp3+) target cells. (B) 
Graph presenting the mean percentages ± SD of NK-induced caspase 3 activation (corrected for spontaneous 
caspase 3 activation) in target for at least three independent experiments. *p < 0.05; **p < 0.01; ***p < 0.001 
versus hTERT-HME1 target cells.
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Finally, to check whether CD56 mRNA expression might influence prognosis in breast cancer patients, we 
took advantage of the KM plotter platform that uses gene expression data and patient survival information down-
loaded from GEO, EGA and TCGA. The Kaplan-Meier survival plots showed that high mRNA expression of 
Figure 6. Induction of CD56 expression in breast cancer cells enhances their sensitivity to NK-92-mediated 
cytotoxicity. CD56-negative MCF-7 and MDA-MB-231 parental cells were transiently transfected with either 
pCMV3-CD56 plasmid or pCMV3 empty plasmid. After 48 hours, the transfected cells were assessed for CD56 
expression by flow cytometry (panel A), for the rate of immune synapse formation and CD56 localization 
by CFSE-labeling, coculture with NK-92 cells at 1:1 effector-to-target ratio for 2 h and immunofluorescence 
microscopy (panel B and C) and for their responsiveness to NK-92-mediated cytotoxicity by calcein-AM 
cytotoxicity assay (panel D). (A) The histograms presented indicate the percentage of CD56-positive cells and 
are representative results from at least five independent experiments. (B) Fluorescence images are representative 
fields from two independent experiments. (C) Graphs presenting the mean rates of synapse formation ± SD 
obtained from two full slides for each condition. (D) Results presented are means ± SD for three independent 
experiments performed each in triplicates. **p < 0.01; ***p < 0.001; ****p < 0.0001.
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CD56 significantly associates with better relapse-free survival (RFS) but not overall survival (OS) (Supplementary 
Fig. 3A). However, as this is data from bulk mRNA, it cannot be distinguished whether the higher CD56 expression 
is actually due to higher expression on tumor cells or whether it is due to greater infiltration of NK cells. Therefore, 
to control for the presence of NK cells within the tumors, the prognostic value of another NK marker; NKp46, 
was also checked and found to be significantly associated with better RFS and OS (Supplementary Fig. 3B). In 
contrast to CD56, NKp46 was not found to be expressed in breast tumor tissues (Supplementary Fig. 4) or cell lines 
(Supplementary Fig. 3C). Thus, together, this data suggests that the good prognostic value of NKp46 would reflect 
the prognostic value of NK cell infiltration in breast tumors and therefore, the good prognostic value of CD56 
mRNA expression in breast tumor tissues might be at least in part due to the enhanced infiltration by NK cells and 
not necessarily related to the expression of this adhesion molecule in tumor cells themselves.
Discussion
In the present study, we checked the potential value of the NK-92 cell line as immunotherapy tool for breast 
cancer treatment and searched for biomarkers and mechanisms of sensitivity to NK-mediated cytotoxicity. 
To our knowledge, the cytotoxic potency of NK-92 cells had never been determined against breast cancer cell 
lines; nonetheless, it was widely analyzed against leukemia cell lines, which were found to be all highly sensitive 
(more than 50% cytotoxicity at very low effector:target ratios; less than 1:1 for most cell lines and less than 9:1 
for the least sensitive ones)31. Consistently, our results showed that K562 leukemia cells, used as positive con-
trol, are highly sensitive to NK-92-mediated lysis (50% cytotoxicity at effector:target ratio less than 1:1). On the 
other hand, almost all breast cancer cell lines (except for 1 out of 9) were found to be resistant to NK-92 cells 
(50% cytotoxicity was not reach at effector:target ratio of 9:1). This in vitro data reflects the differences in NK 
cell-based immunotherapy clinical outcomes, which were successful in hematological cancers17,18, but not in 
breast cancer3,16. In addition to the breast cancer cells, we determined the cytotoxic activity of NK-92 lympho-
cytes against normal mammary epithelial cells and hTERT-immortalized mammary epithelial cells. Whereas 
normal mammary epithelial cells were resistant to NK-92-mediated cytotoxicity, their hTERT-immortalized 
counterparts were highly sensitive. The increased sensitivity of hTERT-immortalized mammary epithelial cells to 
NK-92-mediated lysis could be the consequence of the possible expression of classical ligands for NK-activating 
receptors that might probably be induced by the cellular stress caused by telomerase constitutive expression (data 
not shown; manuscript in preparation). For example, the differential expression analysis of NK regulating genes 
between the hTERT-immortalized mammary epithelial cells (hTERT-HME1) and the normal primary mam-
mary epithelial cells (PMEC) showed that the NK-activating ligand; CD86, could be a candidate gene for such 
hypothesis (Supplementary Fig. 5A). In fact, CD86 seems to be expressed in hTERT-HME1 but not in PMEC. 
Total number 
of tumors (%)
Number of tumors (%)
Pb
High to moderate CD56 
expressiona (30–100%)
Low and absent CD56 
expressiona (0–29%)
Total 99 (100%) 36 (36.4%) 63 (63.7%)
Age 0.52 (NS)
   <60 87 (87.9%) 31 (86.1%) 56 (88.9%)
   ≥60 12 (12.1%) 5 (13.9%) 7 (11.1%)
Tumor size 0.68 (NS)
   ≤2 cm 10 (10.1%) 3 (8.3%) 7 (11.1%)
   2–5 cm 61 (61.6%) 22 (61.1%) 39 (61.9%)
   >5 cm 28 (28.3%) 11 (30.6%) 17 (27%)
Lymph node status
   Negative 58 (58.6%) 24 (66.7%) 34 (54%) 0.06 (NS)
   Positive 41 (41.4%) 12 (33.3%) 29 (46%)
Tumor gradec
   I 0 (0%) 0 (0%) 0 (0%) 0.44 (NS)
   II 54 (56.8%) 18 (51.4%) 36 (60%)
   III 41 (43.2%) 17 (48.6%) 24 (40%)
ER statusd
Negative 42 (42.9%) 15 (41.7%) 26 (42.6%) 0.89 (NS)
Positive 56 (57.1%) 21 (58.3%) 35 (57.4%)
PR statuse
Negative 62 (63.9%) 23 (63.9%) 39 (63.9%) >0.99 (NS)
Positive 35 (36.1%) 13 (36.1%) 22 (36.1%)
Table 1. Immunohistochemical analysis of CD56 expression in breast cancer tissues and relation to standard 
clinicopathological factors. Breast cancer tissue microarray used: BC081120c (US Biomax). aHigh expression 
(70–100% of CD56-positive cells per tissue), moderate expression (30–69% of CD56-positive cells per tissue) 
and low expression (0–29% of CD56-positive cells per tissue); bχ2 Test; cInformation available for 95 patients; 
dInformation available for 98 patients; eInformation available for 97 patients.
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However, the expression of this stress ligand doesn’t seem to be sufficient for the induction of the sensitivity of 
breast precancerous/cancerous cells to NK-92-mediated cytotoxicity as it was also found to be expressed in the 
NK-92-resistant breast cancer cell line HCC1954 (Supplementary Fig. 5A). This hypothesis still needs to be inves-
tigated. Thus, another factor would be responsible for the difference in the responsiveness of breast cancer cells 
to NK-92-mediated cytotoxicity. Independently of the nature of this factor, these observations further support, 
in breast cancer, the previously described concept that NK cells eliminate abnormal (highly proliferative and 
stressed) cells to prevent cancer development while saving normal tissues and that the acquisition, by cancer cells, 
of mechanisms of escape from immune surveillance notably by NK cells allows cancer progression42–44.
The in vitro experimental model used in the present study, which consists of direct NK-92 and target cell 
co-culture, considers the tumor cell-intrinsic mechanism(s) involved in the resistance of breast cancer to 
NK-mediated cytotoxicity, but doesn’t take into account the regulatory effect of the tumor microenvironment45. 
Few studies have examined the tumor cell-intrinsic mechanisms of NK-escape in breast cancer. These mech-
anisms include: (1) the modulation of the expression of molecules involved in NK recognition and activation 
(i.e. increased expression of ligands for NK inhibitory receptors and/or decreased expression of ligands for NK 
activating receptors on target cells)46–48, (2) the secretion of soluble inhibitory factors that alter the function of NK 
cells22,24 and/or (3) the development of resistance to apoptosis23. In our experiments, the target cell supernatants, 
which might contain any potential NK-inhibitory soluble factors, were replaced by fresh media before coculture 
with NK cells; therefore, the secretion of NK-inhibitory factors by NK-92-resistant breast cancer cells might not 
be responsible for the observed resistance. Moreover, since our results showed an association of the decreased 
responsiveness to NK-mediated cytotoxicity with decreased NK degranulation (i.e. activation), our study favors 
the first above-mentioned mechanism of breast cancer escape from NK cells over the third one (i.e. resistance of 
target cells to NK-induced apoptosis). Thus, taken together, these observations suggested that molecules respon-
sible for NK recognition and/or activation are deregulated in the two NK-92-sensitive cell lines (hTERT-HME1 
and BT549) in comparison to the eight NK-92-resistant breast cancer cell lines, which we next tried to uncover.
Comparative gene expression analysis showed a specific expression of CD56 mRNA and protein only in the 
NK-92-sensitive (hTERT-HME1 and BT549), but not in the NK-92-resistant breast cancer cell lines (BT474, 
SKBR3, HCC1954, MDA-MB-231, BT20, T47D, HCC1954 and MCF-7). This observation implies that CD56 is 
a potential predictive biomarker of breast cancer sensitivity to NK-92-mediated cytotoxicity, which seems to be 
tissue specific as the highly sensitive K562 leukemia cells didn’t express this marker.
The value of CD56 as predictive biomarker for NK-92-based immunotherapy in breast cancer depends on the 
actual expression of this protein in patient-derived breast tissues, which had never been previously described. 
Physiologically, CD56 (alias neural cell adhesion molecule) is known to be abundantly expressed in the devel-
oping as well as in the adult human nervous system and plays a pivotal role in neurogenesis, neuronal migra-
tion, and neurite outgrowth49–51. Furthermore, CD56 is considered the archetypal phenotypic marker of NK 
cells52,53, but has also been detected on other lymphoid cells, including a subset of T cells and dendritic cells54–56. 
Therefore, to gain insight into the status of CD56 in breast cancer tissues, we analyzed the expression of this pro-
tein by IHC in 99 patient-derived breast cancer tissues and revealed high inter- and intratumoral heterogeneity 
regarding CD56 expression. Thus, based on our hypothesis that CD56 is a predictive biomarker for responsive-
ness to NK-92-mediated cytotoxicity, if adoptive NK-92 transfer is to be used in breast cancer patients, we would 
expect, unresponsiveness in more than two-thirds of the cases (no or very low % of CD56 expressing cells), and at 
best, very low responsiveness with rapid relapse in 12.1% of the cases (high intratumoral heterogeneity regarding 
CD56 expression; 30–69% CD56-positive cells) and better responsiveness with longer RFS in 24.2% of the cases 
(70–100% of CD56-positive cells per tissue). However, these expectations are very optimistic as they don’t take 
into consideration the accessibility of NK-92 cells to the tumor cells (even if administered after surgical removal 
of the breast tumor) neither the regulatory effect of the tumor microenvironment which might lower the immu-
notherapeutic potential of these lymphocytes45. Therefore, preclinical studies using patient-derived breast cancer 
xenograft-mouse models would allow the verification of whether the high cytotoxic activity of NK-92 cells against 
CD56-positive breast cancer cells is maintained in vivo and the identification of potential combinatory treatment 
in addition to NK-92 adoptive transfer to counteract any possible inhibitory effect of the tumor microenvironment.
Noteworthy, we also found that 80% (8 out of 10) of the normal breast tissues express CD56, consistently with 
the primary mammary epithelial cell line (PMEC). Thus, this study describes for the first time CD56 expression 
in tissues of mammary origin and suggests that the loss of CD56 expression might be a mechanism of breast 
cancer escape from NK-immunity. Interestingly, high mRNA expression of CD56 significantly associated with 
better prognosis.
However, the good prognostic value of CD56 mRNA expression in breast tumor tissues might be at least in 
part due to the enhanced infiltration by NK cells and not necessarily related to the expression of this adhesion 
molecule in tumor cells themselves.
The role of CD56 as predictive biomarker for NK-92-based immunotherapy could also be valid for other types 
of cancer in addition to breast cancer. In fact, among the solid tumor cancers, the success of NK cell-based immu-
notherapy has been limited to neuroblastoma and glioblastoma16,57,58. As these tumors are of neurectodermal 
origin and thereby strongly express CD56 molecules59,60, we can hypothesize that CD56 expression might account 
for the responsiveness of these tumors to NK-based immunotherapy, which needs to be experimentally tested.
In addition, to its role as predictive biomarker of responsiveness to NK-92-mediated cytotoxicity, we found 
that CD56 plays an active role in enhancing the sensitivity of breast cancer cells to these lymphocytes. In fact, the 
ectopic expression of this adhesion molecule in CD56-negative breast cancer cells enhanced their sensitivity to 
NK-92-mediated killing. Consistently with our finding that CD56 molecules expressed on target cells are function-
ally involved in inducing NK cell-mediated cytotoxicity; on the other hand, CD56 molecules on NK cells were found 
to play a similar role. In fact, a study by Nitta et al. showed that neutralization of CD56 molecules expressed on NK 
cells inhibits the cytotoxicity of these lymphocytes only towards target cells that express CD56 (i.e. tumor cell lines of 
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neuroectodermal origin) but not towards CD56-negative leukemic targets61. Together, this finding and ours suggest 
that both CD56 molecules expressed on NK cells and on target cells are involved in enhancing NK function through 
homotypic interactions, consistently with the homotypic binding of this adhesion molecule demonstrated in neural 
and muscle tissues40. In agreement with this hypothesis, we found that CD56 molecules on NK-92 cells and those 
on CD56-positive target cells interact together to enhance the formation and stabilization of the immunological 
synapse. Furthermore, the accumulation of CD56 molecules at the immunological synapse was accompanied by 
cytotoxic granzyme B transfer from NK-92 to the CD56-expressing target cells and by induced caspase 3 activation 
in target cells. However, this resulting polarization of cytotoxic granules, transfer of granzymes into target cells and 
induction of apoptosis can be the consequence of either the spatial clustering of the NK regulatory receptors at the 
CD56-mediated interaction between NK-92 and target cells thereby increasing the efficacy of intracellular signal-
ing11,12 or the direct CD56-mediated regulation of signaling pathways that control lytic granule polarization at the 
immune synapse. Although the role of CD56 in the latter process was not previously described, CD56 is known to 
regulate molecules such as fyn that are essential for promoting lytic granule polarization to the lytic synapse40,62. 
Furthermore, comparison of the differential gene expression of all known-to-date ligands for NK regulatory recep-
tors63 between the different NK-92-sensitive and resistant breast precancerous and cancerous cell lines showed that 
three ligands CD70, CD72 and COL3A1 have an expression profile comparable to that of CD56 (Supplementary 
Fig. 5A). Among these, only CD72 could be involved in the increased sensitivity of these target cells to NK-mediated 
cytotoxicity. In fact, on the one hand Col3A1 is a NK-inhibitory molecule and on the other hand the receptor for 
CD70 (i.e. CD27) is not expressed in NK-92 cells (Supplementary Fig. 5B). However, even if the NK-activating 
ligand, CD72, whose corresponding receptor (SEMA4D) is expressed by NK-92 cells (Supplementary Fig. 5B) might 
play a role in inducing breast cancer sensitivity to NK-mediated cytotoxicity (a hypothesis that needs to be tested), 
the role of CD56 in this same mentioned process is independent of the expression CD72. In fact, as shown in the 
present study, the induction of CD56 expression in MCF-7 and MDA-MB-231 which are CD72-negative strongly 
enhanced their sensitivity to NK-mediated cytotoxicity.
Whatever the exact mechanism involved, our observations strongly suggest that CD56 expression on breast 
cancer cells enhances their susceptibility to NK-92 mediated cytotoxicity and therefore induction of its expression 
in CD56-negative cells might become a novel attractive approach for sensitizing initially resistant breast tumors.
Although in this present study we focused on the NK-92 cell line, which presents several advantages over the 
other sources of NK cells26, our conclusions might also be applicable on other types of NK cells (such as periph-
eral blood NK cells or stem cell-derived NK cells) since they also express CD56. However, in contrast to NK-92 
cells, normal NK cells express the NK inhibitory receptors; KIRs64. Therefore, further experiments using other 
sources of NK cells could be performed to address whether the NK-activating role of CD56 molecules on target 
cells could counteract the KIR-mediated inhibitory signals, which is not concerning in the case of NK-92 cells 
that lack most KIRs64.
In conclusion, this study identified CD56 as predictive biomarker for breast cancer sensitivity to 
NK-92-mediated cytotoxicity and as new regulator of the NK-immune function by enhancing the interaction 
between NK and breast cancer cells and thereby inducing immune synapse formation and stabilization. Thus, 
NK-92 cell line is a potential effective immunotherapy tool for CD56-positive breast cancer treatment and induc-
tion of CD56 expression combined with NK-92-adoptive transfer might become a novel attractive approach for 
sensitizing initially resistant CD56-negative breast tumors.
Methods
Cell culture. All human breast tissue derived cell lines (hTERT-HME1, PMEC, BT20, BT474, BT549, 
HCC1500, HCC1954, MCF-7, MDA-MB-231, SKBR3 and T47D), the leukemia cell line K562 and NK-92 cell 
line were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA) and cultured in 
the conditions recommended by ATCC. When the effector (NK-92) and target (breast tissue derived cell lines 
and K562) cells were cocultured together for assays, the effector complete medium without IL-2 (i.e. Alpha 
Minimum Essential medium without ribonucleosides and deoxyribonucleosides but with 2 mM L-glutamine 
and 1.5 g/L sodium bicarbonate supplemented with 12.5% horse serum, 12.5% fetal bovine serum, 0.2 mM ino-
sitol, 0.1 mM 2-mercaptoethanol, 0.02 mM folic acid, 100 units/ml penicillin and 100 µg/ml streptomycin) was 
used. 16–24 hours before effector-target coculture, NK-92 cells were cultured at 500,000 cells/mL in fresh effector 
complete medium containing 300 U/mL recombinant human IL-2 (PeproTech, Hamburg, Germany). All other 
media, serum and supplements were from Life Technologies (ThermoFisher Scientific, Waltham, MA, USA), 
Sigma-Aldrich (St. Louis, MO, USA) or ATCC.
Transient transfection. Cells were grown to 70–80% confluence and transfected with pCMV3-NCAM1 
plasmid (2.5 μg; Cat # HG10673-UT Sinobiological, Wayne, PA, USA) or empty pCMV3 plasmid (2.5 μg; Cat # 
CV011 Sinobiological) using Lipofectamine 3000 transfection kit (Cat # L3000-015, Invitrogen, ThermoFisher 
Scientific) according to the manufacturer’s protocol. At 48 hours post-transfection, cells were collected for assess-
ment of transfection efficiency and subsequent analyses.
Calcein-Acetyoxymethyl (calcein-AM) cytotoxicity assay. Calcein-AM cytotoxicity assay was per-
formed as previously described37. Target cells were resuspended in complete medium at a final concentration of 
1 × 106 cells/mL and incubated with 15 μM calcein-AM dye (Molecular Probes, Eugene, OR, USA) for 30 min at 
37 °C with occasional shaking. After two washes in complete medium, target cells were adjusted to 1 × 105 cells/mL 
in effector complete medium without IL-2. NK-92 cells were counted in effector complete medium without IL-2 
and adjusted to 1 × 105 cells/mL. Then, the effector and target cells were seeded in V-bottom 96-well plate at 
effector-to-target ratios ranging from 20:1 to 0.62:1, in triplicates. Each well contained from 1 × 105 to 3 × 103 
NK-92 in 100uL and 5 × 103 target cells in 50 μl. Six replicate wells for spontaneous (only target cells in effector 
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complete medium without IL-2) and maximum release (only target cells in medium plus 10% Triton X-100) were 
added. After incubation at 37 °C in 5% CO2 for 4 hours, 75 μL of each supernatant was harvested and transferred 
into new flat-bottom 96-well plate. Samples were measured using FLUOstar Omega microplate reader (excitation 
filter: 485 ± 9 nm; band-pass filter: 530 ± 9 nm). Data was expressed as arbitrary fluorescent units corresponding 
to the fluorescent calcein released in the supernatant after lysis of target cells and cytotoxicity percentages were 
calculated using this formula:
=
−
−
×Cytotoxicity Test release Spontaneous release
Maximum release Spontaneous release
% 100
Flow cytometry. Cells were washed twice with cold phosphate-buffered saline (PBS) and incubated with 
PE-conjugated anti-CD56 antibody (1:100 dilution; Cat # 130-090-755 Miltenyi Biotec, Auburn, CA, USA) or 
APC-conjugated anti-CD56 antibody (1:100 dilution; Cat # 318310 Biolegend, San Diego, CA, USA) or with their 
respective isotype control antibodies PE-conjugated mouse IgG1 (1:100 dilution; Cat # 130-092-212 Miltenyi 
Biotec) or APC-conjugated mouse IgG1κ (1:100 dilution; Cat # 400122 Biolegend) for 20 minutes at 4 °C. Then, 
the cells were washed twice with cold PBS. Data was acquired on BD Accuri™ C6 flow cytometer and analyzed 
using FlowJo software.
Degranulation assay. One day before assay, 2.5 × 106 target cells were labeled with 0.5 uM CellTrace CFSE 
(Carboxyfluorescein succinimidyl ester) (Cat # C34554 ThermoFisher Scientific) and incubated at 37 °C over-
night. The next day, CFSE-labeled target cells and NK-92 cells were cocultured at 1:1 effector-to-target ratio at 
37 °C for 2 hours and stained with Alexa Fluor® 647-conjugated anti-CD107a antibody (1:100 dilution; Cat # 
562622 BD Biosciences) or Alexa Fluor® 647-conjugated mouse IgG1κ isotype control (1:100 dilution; Cat # 
557732 BD Biosciences, San Jose, CA, USA). Then, cells were washed twice with cold PBS and analyzed on BD 
Accuri™ C6 flow cytometer and FlowJo software.
Active caspase 3 apoptosis assay. One day before assay, 2.5 × 106 target cells were labeled with 0.5 uM 
CellTrace CFSE and incubated at 37 °C overnight. The next day, CFSE-labeled target cells and NK-92 cells were 
cocultured at 1:1 effector-to-target ratio at 37 °C for 2 hours. After two washes with cold PBS, cells were fixed 
using BD Cytofix/Cytoperm solution (Cat # 51-6896KC BD Biosciences). After fixation, cells were washed twice 
with BD Perm/Wash buffer (Cat # 51-6897KC BD Biosciences) and incubated with PE-conjugated anti-active 
caspase-3 antibody (Cat # 51-68655X BD Biosciences) for 30 minutes at room temperature. The cells were then 
washed twice with BD Perm/Wash buffer and analyzed on BD Accuri™ C6 flow cytometer and FlowJo software.
Immunofluorescence. Cells were grown to 70–80% confluence on cover glass slides (Menzel-Gläser; 
Braunschweig, Germany), washed twice with PBS and fixed in 4% paraformaldehyde in 0.1 M phosphate buffer 
(pH 7.4) for 20 minutes at room temperature. The cells were permeabilized for 15 minutes with 0.4% Triton X-100 
in PBS (PBST), and blocked with 6% bovine serum albumin (BSA) in PBST for at least 1 hour at room tempera-
ture. After removing of the blocking solution, the cells were incubated with mouse anti-human CD56 (NCAM) 
antibody (1:250 dilution; Cat # 318310 Biolegend) or mouse IgG1κ isotype control (1:250 dilution; Cat # 400122 
Biolegend) at 4 °C overnight. The cells were washed three times with tris-buffered saline with 0.3% Tween 20 
(TBST) and then incubated with the secondary antibody Alexa Fluor 568-conjugated donkey anti-mouse IgG 
(1:500 dilution; ThermoFisher Scientific) for 45 minutes at room temperature. The slides were washed three times 
with TBST, rinsed once with PBS and mounted in Vectashield mounting medium containing 1.5 μg/mL DAPI 
(Vector Laboratories, Burlingame, CA, USA). The slides were kept protected from light. There were examined and 
imaged under Zeiss fluorescent microscope and the images were processed using the Adobe Photoshop software.
Immune synapse formation assay. NK-92 cells were co-cultured with CFSE-labeled target cells in 
a 96-well plate at 1:1 ratio (150,000 cells/well) for 2 hours at 37 °C. Cell conjugates were then transferred to 
Poly-L-lysin-coated coverslips placed in 24-well plates. To visualize the interactions between NK-92 and 
CFSE-labeled target cells, the conjugates were fixed, permeabilized, blocked and stained using the same procedure 
as in “Immunofluorescence” method above. Alternatively, immune synapse was determined by staining the actin 
cytoskeleton polymerization at the contacts between NK-92 and target cells (without CFSE labeling) using Alexa 
Fluor® 488 Phalloidin (Cat # A12379 Molecular Probes, Life technologies). In this alternative method lacking 
the labeling of target cells, the latter could be distinguished from NK cells based on the size of their nucleus. In 
fact, in control single cultures (NK alone and target alone) stained with DAPI as in immune synapses involving 
CFSE-labeled target cells, NK cells were found to have a bigger nucleus than hTERT-HME1 target cells. Therefore, 
in the cell conjugate forming the immune synapse, the cell that has a bigger nucleus is identified as “NK” and the 
cell with the smaller nucleus is identified as the target “T”.
The rate of synapse formation was quantified by counting in each representative field or slide the number of 
NK cells bound to target cells (NK-T) and the number of NK cells unbound to target cells (NK alone), then using 
the formula:
=
−
− +
×Rate of synapse formation (%) number of NK T
number of NK T number of NK alone
100
The localization of CD56 or granzyme B proteins relative to the immune synapse was determined using the 
primary antibodies mouse anti-CD56 (1:125 dilution, Biolegend) or mouse anti-Granzyme B (1:125 dilution; 
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Cat # MA1-80734 ThermoFisher Scientific), respectively, followed by the secondary antibody Alexa Fluor® 
568-conjugated donkey anti-mouse IgG (1:500 dilution; Thermo Fisher Scientific).
Breast cancer tissue array immunohistochemistry (IHC). Breast cancer tissues microarray slides 
were purchased from US Biomax (BC081120c). Each slide contained 110 specimens (100 cases of invasive ductal 
carcinoma and 10 normal breast tissue). The paraffin-embedded sections (5 μm thickness) were deparaffin-
ized, rehydrated through descending grades of ethanol, and washed with PBS. For antigen retrieval, the slides 
were incubated in 10 mM Sodium citrate containing 0.05% Tween 20, pH 6.0 for 3 hours at room temperature 
and rinsed two times with 0.1 M PBS with 0.2% Triton X-100, pH 7.4 (PBST). To block non-specific protein 
binding, sections were incubated in 6% BSA in PBST overnight at 4 °C, then were incubated for 24 hours at 
4 °C with mouse anti-human CD56 (NCAM) antibody (1:250 dilution; Cat # 318310, Biolegend) or with mouse 
anti-human NKp46 antibody (1:250 dilution; Cat # 331918, Biolegend). The primary antibodies were diluted in 
2% BSA in PBST. After rinsing the sections with PBST for three times (15 min each), they were incubated for 
2 hours at room temperature with Alexa Fluor 568-conjugated donkey anti-mouse IgG (1:500 dilution; Thermo 
Fisher Scientific, USA). After three rinses with PBST, Vectashield mounting medium containing 1.5 μg/mL DAPI 
was added to the slides and then covered with cover slips. The slides were kept away from light and the images 
were captured using a Zeiss fluorescent microscope.
Semi-quantitative RT-PCR. Total RNA was extracted from cells using RNeasy Mini Plus Kit 
(Qiagen, Hilden, Germany) following the manufacturer’s recommendations. The concentration (ng/
mL) and the purity of the isolated RNA were measured using NanoDrop 2000 UV-Vis Spectrophotometer 
(ThermoFisher Scientific). 1 µg RNA from each sample was reversely transcribed using SuperScript™ IV 
First-Strand Synthesis System (Invitrogen) as per the manufacturer’s instructions. cDNA templates were 
added to PCR Master Mix (ThermoFisher Scientific) then amplified using specific primers for CD56 
(5′-CATCACCTGGAGGACTTCTACC-3′ and 5′-CCAAGGACTCCTGCCCAATG-3′) or GAPDH housekeep-
ing gene (5′-ACGACCACTTTGTCAAGCTCATTTC-3′ and 5′-GCAGTGAGGGTCTCTCTCTTCCTCT-3′). The 
PCR reactions were carried in a thermal cycler with the following protocol: an initial denaturation step for 3 minutes 
at 95 °C, followed by 35 cycles of amplification (95 °C for 30 seconds, 59 °C for 30 seconds, and 72 °C for 45 seconds), 
and a final extension step for 10 minutes at 72 °C. PCR products were separated on 2% agarose gel supplemented with 
ethidium bromide. Images were visualized with BioRad Chemidoc XRS system and analyzed by ImageJ software.
RNA-seq sample preparation, library construction and sequencing. Total RNAs extracted from 
cells using RNeasy Mini Plus Kit were checked on Agilent Bioanalyzer 2100 system to measure the integrity of 
the samples then on Thermo QuBit 2.0 Flourimeter to measure their concentration. All samples that have good 
quality were taken forward to prepare the libraries for the sequencing. Libraries were prepared using TruSeq 
mRNA Stranded Library Prep Kit (Illumina Inc) by following the manufacturer’s protocol. Briefly, mRNAs were 
captured by Oligo dT selection and fragmented. Fragments were then subjected to end filling, A-tailing before 
ligating them with Illumina adaptor. Ligated fragments underwent 12 rounds of PCR cycles to amplify the frag-
ments in order to have enough sequencing libraries. The quality control analyses of sequencing libraries were 
performed again by QuBit for quantification and on Agilent technologies 2100 Bioanalyzer chip to measure the 
quality and to measure the library size. The quality control passed libraries were sequenced on an Illumina HiSeq 
4000 instrument by Illumina Sequencing-By-Synthesis (SBS) method. 2.5 nM were loaded for each library and 12 
samples were loaded on each lane of the HiSeq 4000 flow cell. Paired end data were generated for 300 cycles and 
each sample having a minimum of 25 million cluster reads.
Bioinformatic analyses. Quality control (QC) for the raw reads was performed with the FastQC version 
0.11.5 as per the FastQC-project parameter recommendations (http://www.bioinformatics.babraham.ac.uk/pro-
jects/fastqc/). Besides, RNA-Seq analysis workflow was designed and conducted through the CLC Biomedical 
Genomics Workbench v5.0.1 (QIAGEN Aarhus, Denmark). The first step incorporated a QC enhancement which 
included length (less than 60 bp) and quality trimming of the short sequence reads. Then, the paired-end short 
fragments reads were assembled, mapped and annotated against the Homo Sapiens RefSeq GRCh37 genome 
and transcripts build. Next, the gene expression profile was estimated for each gene using the total count where 
the reported level is the number of reads that map to the exons of that gene. For the hierarchical clustering of the 
samples’ expression patterns similarity over their genes, the Create Heat Map tool was used. Candidate genes 
are normalized by applying the trimmed mean of M-values normalization method (TMM). Then, the clustering 
algorithm was defined by the Euclidean distance measurement and the complete linkage.
Statistical analysis. Statistical significance of differences between experimental groups was performed by 
Student’s t-test and relationships between CD56 expression and clinical parameters were identified by chi-square 
(χ2) test, using the GraphPad Prism 7 software (San Diego, CA, USA). Differences were considered significant at 
confidence levels greater than 95% (P < 0.05).
Data Availability
RNA sequencing datasets generated during the current study are available in the Zenodo repository (https://
doi.org/10.5281/zenodo.2784989, https://doi.org/10.5281/zenodo.2813842 and https://doi.org/10.5281/zeno-
do.2918674). The other datasets are available in the supplementary information of this article or from the corre-
sponding author on reasonable request.
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